Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Holli Hutcheson Dilks, PhD
Director, Personalized Medicine Operations
Holli Hutcheson Dilks joined Sarah Cannon in 2014 as the director of Personalized Medicine Operations. In this role, she is responsible for providing scientific support and direction for the development and implementation of Sarah Cannon's global molecular profiling/personalized medicine Initiative. She is also responsible for the development of biomarker strategies in support of disease area programs and individual clinical trials.
Prior to joining Sarah Cannon, Dr. Dilks served as technical director of the Vanderbilt Technologies for Advanced Genomics Core Resource and director of core resources at the Center for Human Genetics Research at Vanderbilt University Medical Center. She also served as a program director for SRI International. Dilks received her B.A. from Lipscomb University, her PhD. in Molecular Physiology and Biophysics from Vanderbilt University and performed her postdoctoral Cancer Research Training Award fellowship at the National Cancer Institute (NIH). Additionally, she served as visiting scientist at Broad Institute of MIT and Harvard. Additionally, Dilks currently serves as an adjoint assistant professor for the Department of Pharmaceutical Sciences at Lipscomb University College of Pharmacy.